Pelthos Therapeutics (PTHS) News
NYSE: PTHSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
6.38-0.61 (-8.73%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PTHS news summary
We found 4 recent headlines mentioning Pelthos Therapeutics (PTHS): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. PTHS is making an outsized move today, down 8.73% at $6.38, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Pelthos (PTHS) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Pelthos Therapeutics headlines
- Pelthos (PTHS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdateZelsuvmi ® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 2025GlobeNewswire
- Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split(RTTNews) - The healthcare sector saw a busy week, with several companies securing regulatory approvals, announcing workforce restructuring, and advancing strategic business deals.NasdaqABT, AGIO, BEAT, BIOA
- Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the SkinStrategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB)GlobeNewswire